US Industry Hauls Post-Brexit UK Over The Coals
IP Protections & Access To Innovation Seen As Weak Points
PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.
